Pepcid Rx-to-OTC switch
FDA's Nonprescription Drugs & Gastrointestinal Drugs Advisory Committees will consider J&J/Merck's application for over-the- counter status of the H-antagonist Pepcid (famotidine) on July 29. J&J/Merck is seeking approval for the drug as an OTC for treatment and prevention of episodic heartburn. SmithKline Beecham is seeking OTC status for a similar indication for Tagamet (cimetidine); the advisory committees rejected an approval recommendation last September. However, SmithKline expects the OTC Tagamet NDA to be revisited on July 27. FDA has not yet officially announced a meeting on Tagamet
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth